PMP22 and Charcot-Marie-Tooth disease type 1A: We demonstrate long-lasting therapeutic effects following a single, clinically relevant lumbar intrathecal injection in a mouse model of CMT1A that expressed both human PMP22 and mouse Pmp22 gene products.